AngioDynamics (ANGO) Earning Somewhat Positive Media Coverage, Report Finds
Headlines about AngioDynamics (NASDAQ:ANGO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.0476612591728 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of AngioDynamics (ANGO) opened at $17.34 on Thursday. The company has a market capitalization of $639.59, a price-to-earnings ratio of 25.25, a P/E/G ratio of 1.79 and a beta of 1.05. AngioDynamics has a 12-month low of $14.80 and a 12-month high of $18.85. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.48.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). The company had revenue of $85.40 million during the quarter, compared to analysts’ expectations of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.17 earnings per share. equities analysts anticipate that AngioDynamics will post 0.65 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on ANGO. BidaskClub cut AngioDynamics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. KeyCorp reiterated a “hold” rating on shares of AngioDynamics in a report on Friday, September 29th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a report on Sunday, October 8th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $18.60.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.